RYTMRYTMHealthcare · Biotechnology

RYTM Stock Forecast: Rhythm Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 17 Nov 2026
$117
+8.49% on the day

The 19 Wall Street analysts covering Rhythm Pharmaceuticals, Inc. hold a median 12-month price target of $142 — +21.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 84 of 100 as at 16 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$8.0B
Ticker Nerd rank
84/ 100
Median analyst target
$142
Analysts covering
19
Revenue$71.3M+46.9% y/y
Operating income−$48.6M
Net income−$49.3M
Free cash flow−$9.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+2.3%
1M
+35.3%
YTD
+8.9%
1Y
+15.8%
From 52W high
−0.9%
From 52W low
+53.8%
$76
$118
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

RYTM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Rhythm Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 16 Nov 2026
84/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
91
Accruals
86
Quality
85
Volatility
82
Issuance
80
Momentum
67
Growth
53
Revisions
46
Size
18

Value (91): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Revisions (46): Analysts have, on balance, been cutting their forecasts.

Size (18): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

RYTM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RYTM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$80$100$120$140$160$180Jan 26Apr 26Jul 26Oct 26RYTMHigh $168Median $142Low $112

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says19 analysts
17 Buy2 Hold0 Sell
Low $112Median $142High $168

The green dot is the last close — the median target sits +21.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
7 Nov 2026JP MorganMaintainsOverweight—
6 Nov 2026JP MorganMaintainsOverweight$145 → $142
5 Nov 2026GuggenheimMaintainsBuy$143 → $147
4 Nov 2026CitizensMaintainsMarket Outperform$160 → $166
3 Nov 2026NeedhamMaintainsBuy$130 → $114
16 Oct 2026William BlairInitiatesOutperform—
16 Oct 2026William BlairInitiatesOutperform—
15 Oct 2026JP MorganMaintainsOverweight—
15 Oct 2026JP MorganMaintainsOverweight$146 → $145
12 Oct 2026HC Wainwright & Co.MaintainsBuy—
12 Oct 2026HC Wainwright & Co.MaintainsBuy$105 → $130
8 Oct 2026RBC CapitalMaintainsOutperform—
8 Oct 2026RBC CapitalMaintainsOutperform$155 → $159
14 Sept 2026Leerink PartnersAssumesOutperform$133
28 Aug 2026Deutsche BankInitiatesHold$120
28 Aug 2026Deutsche BankInitiatesHold—
7 Aug 2026JP MorganMaintainsOverweight$145 → $146
7 Aug 2026JP MorganMaintainsOverweight—
5 Aug 2026CitigroupMaintainsBuy$142 → $143
5 Aug 2026CitigroupMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

RYTM appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

RYTM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 17 Nov 2026, Rhythm Pharmaceuticals, Inc. returned +15.8% against +11.2% for the S&P 500, dividends included.

RYTM vs S&P 500, last 12 monthsTotal return, rebased to 100
708090100110120Jan 26Apr 26Jul 26Oct 26RYTMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

RYTM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
4
Analysts cutting
8
Fundamentals

Rhythm Pharmaceuticals, Inc. (RYTM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−37.0×

Cheaper than 98% of US stocks

Price / sales
28.4×

Cheaper than 7% of US stocks

Price / book
90.6×

Cheaper than 2% of US stocks

EV / EBITDA
−42.3×

Cheaper than 94% of US stocks

Growth & margins
Revenue growth (YoY)
79.6%

Higher than 91% of US stocks

Earnings growth (YoY)
46.9%

Higher than 74% of US stocks

Gross margin
87.5%

Higher than 95% of US stocks

Operating margin
−66.7%

Higher than 16% of US stocks

Net margin
−69.0%

Higher than 8% of US stocks

Returns & dividend
Return on equity
−78.0%

Higher than 16% of US stocks

Return on assets
−24.6%

Higher than 17% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Rhythm Pharmaceuticals, Inc. (RYTM) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Rhythm Pharmaceuticals, Inc. has a market value of $8.0B and an enterprise value of $7.9B.

  • Revenue in the twelve months to 30 June 2026: $239.9M. The latest quarter grew 79.6% year on year.

  • Net income over the same four quarters: −$205.3M, a −85.6% net margin.

  • Diluted earnings per share, trailing twelve months: −$3.11.

  • Free cash flow in the twelve months to 30 June 2026: −$106.3M.

  • Shares outstanding: 68.8M.

  • Trailing P/E: −37.0×; forward P/E: −88.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Rhythm Pharmaceuticals, Inc. employs 414 people — $580K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 17 Nov 2026

Data provided by Twelve Data

Peers

RYTM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
RYTMRhythm Pharmaceuticals, Inc.$8.0B84
CYTKCytokinetics, Inc.$7.4B61
CORTCorcept Therapeutics, Inc.$7.4B75
CGONCG Oncology, Inc.$7.5B36
AXSMAxsome Therapeutics, Inc.$7.1B73
TWSTTwist Bioscience Corp.$6.9B62
PTGXProtagonist Therapeutics, Inc.$8.0B89

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Rhythm Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RYTM news & analysis

Rhythm Pharmaceuticals Says Rare Obesity Drug Delivers Sustained Two-Year BMI Reductions

Benzinga · 17 Nov 2026positive

Rhythm Pharmaceuticals presented two-year Phase 3 setmelanotide results at ObesityWeek 2026, reporting sustained weight reductions in acquired hypothalamic obesity. The company also presented global diagnostic criteria intended to support earlier diagnosis.

Why it matters — The update concerns clinical results and diagnosis for a condition targeted by Rhythm's setmelanotide program.

Rhythm Pharmaceuticals Announces Presentation of New Data at ObesityWeek® 2026

GlobeNewsWire · 16 Nov 2026positive

Rhythm Pharmaceuticals announced that new data will be presented at ObesityWeek 2026. Two-year Phase 3 TRANSCEND results showed that continuous setmelanotide therapy sustained BMI reductions in patients with acquired hypothalamic obesity.

Why it matters — The reported sustained BMI reductions provide clinical-trial information relevant to watchers of Rhythm Pharmaceuticals and its setmelanotide program.

Rhythm Pharmaceuticals: Bull Case Intact, But The Market Is Pricing In A Lot

Seeking Alpha · 10 Nov 2026neutral

Rhythm Pharmaceuticals reported strong commercial momentum, with IMCIVREE sales up 79.5% year over year and a broadening prescriber base in acquired HO. The article says the elevated 27.4x trailing-sales valuation reflects high growth and launch expectations, while takeover speculation, including a reported $124-per-share AstraZeneca bid, supports the share price and adds a premium over fundamentals.

Why it matters — RYTM watchers may weigh commercial growth against a valuation that the article says embeds high expectations and takeover speculation.

FAQ

Frequently asked questions about RYTM stock

What is the RYTM stock price forecast for 2026-2027?

The 19 Wall Street analysts covering Rhythm Pharmaceuticals, Inc. have a median 12-month price target of $142, with estimates ranging from $112 to $168. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RYTM stock a buy right now?

Of the 19 analysts covering Rhythm Pharmaceuticals, Inc., 17 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Rhythm Pharmaceuticals, Inc. 84 out of 100 across roughly 4,600 US stocks as at 16 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RYTM?

As at 16 Nov 2026, Rhythm Pharmaceuticals, Inc. ranks 84 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (91 of 100).

Will RYTM stock go up?

No one can know that. What the data says: the median 12-month target from 19 analysts implies +21.8% from the last close, and Ticker Nerd's factor model ranks Rhythm Pharmaceuticals, Inc. 84 out of 100 as at 16 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RYTM stock forecast for 2030?

No analyst covering Rhythm Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RYTM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $112 to $168 over the next 12 months.

How has RYTM stock performed over the past year?

Rhythm Pharmaceuticals, Inc. returned +15.8% over the 12 months to 17 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Rhythm Pharmaceuticals, Inc. do?

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare neuroendocrine diseases.

What is the latest news on RYTM?

The most recent item we track (Benzinga, 17 Nov 2026): "Rhythm Pharmaceuticals Shares See Volume; Traders Circulate M&A Rumors At $150/Share". The headline says Rhythm Pharmaceuticals shares saw volume as traders circulated an M&A rumor at $150 per share. The excerpt provides no further details or confirmation.

Company

About Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare neuroendocrine diseases. The company’s lead product, IMCIVREE (setmelanotide), is a precision medicine used to treat severe obesity and hyperphagia associated with specific melanocortin-4 receptor pathway disorders and acquired hypothalamic obesity. Rhythm Pharmaceuticals serves patients with serious rare conditions that are often underserved by conventional obesity treatments, and its work centers on targeted treatments designed for defined genetic and clinical populations. Based in Boston, Massachusetts, and founded in 2008, the company operates within specialty medicine, where it addresses unmet needs in rare metabolic and endocrine diseases through approved therapies and ongoing clinical development.

CEO Dr. David P. Meeker M.D. · 414 employees · United States · https://rhythmtx.com